CanPharma has launched and is participating in various projects in the field of medical Cannabis. Globally, more and more countries are opening their healthcare systems to medical cannabis therapies, and also the acceptance among healthcare professionals for this topic is growing. With various projects along the entire value chain, we are driver of this change and ensure that Canpharma will contribute in shaping the future of cannabis.
KSK Labs is a producer of CBD-based products and is currently providing various CBD products under t’s brandname “myCBD” to several countries in Europe.
UNG Labs is a pharmaceutical company that provides under its product brand “CBDinol” innovative cannabis-based solutions to improve the welfare and quality of life of people around the world.
Kalapa Clinic was the first medical consultancy in Europe, specialized on treatments with cannabinoids. Doctors specialised in cannabinoid therapy offer comprehensive medical advice – for patients and for medical and pharmaceutical professionals.
Among others, the experts of the Kalapa Clinic consulted CanPharma regarding the development of a product-portfolio that meet the therapeutic requirements for an appropriate cannabis treatment
Together with CBM Labs, we are focusing on the bio-synthetic production of cannabinoids. CBM Labs is based in the Netherlands and already filed in several patents in order to develop formulations based on cannabinoids. Furthermore, CanPharma will provide CBM Labs with cannabis-based pharmaceuticals for research purposes and CBM Labs will support CanPharma to improve the quality of its product varieties to ensure patient-oriented medicine.